新桥生物 NBP 深 沪
等待开盘 06-30 09:30:00 美东时间
1.98
+0.340
+20.73%
华盛通- 最 高2.11
- 今 开1.695
- 成交量 431.43万股
- 最 低 1.69
- 昨 收 1.64
- 总市值 2.29亿
- 52周最高 6.79
- 市盈率 静 --
- 换手率 3.73%
- 52周最低 1.46
- 委 比 93.00%
- 总股本 1.16亿
- 历史最高 85.40
- 量 比 16.16
- 振 幅 25.61%
- 历史最低 0.595
- 每 手 1
- 风险率 1.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NovaBridge Biosciences appoints Srishti Gupta as CEO
NovaBridge Biosciences (NBP) appointed Srishti Gupta as CEO and a member of its board, effective July 1, succeeding Xi-Yong (Sean) Fu, who is stepping down. Fu will remain with the company in an advis...
06-29 19:23
NovaBridge Biosciences Says FDA Grants Fast Track Designation To Givastomig In First-Line HER2-Negative Metastatic Gastric Cancer
Registrational Phase 3 Trial Expected to Begin as Early as Q4 2026 Detailed Phase 1b Data Expected to be Presented at a Major Medical Conference in H2 2026 ROCKVILLE, Md., June 16, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (NASDAQ:NBP) (NovaBridge or the Company) a global biotechnology platfor...
06-16 19:17
NovaBridge Biosciences Receives FDA Fast Track Designation for Givastomig in First-Line HER2-Negative Metastatic Gastric Cancer
NovaBridge Biosciences announced that the FDA has granted Fast Track Designation to givastomig, a CLDN18.2 x 4-1BB bispecific antibody, for the treatment of previously untreated HER2-negative advanced or metastatic gastroesophageal adenocarcinomas (GEA) with CLDN18.2 and PD-L1 positive tumors. Phase 1b data showed strong efficacy and tolerability when combined with immunochemotherapy, supporting its potential as a leading CLDN18.2-targeted therap...
06-16 11:00
NovaBridge to Present at the 2026 Jefferies Global Healthcare Conference
NovaBridge Biosciences announced that its senior management will participate in the 2026 Jefferies Global Healthcare Conference on June 4, 2026. The event will feature a company presentation at 3:10 PM ET and one-on-one investor meetings. NovaBridge, a global biotech company focused on innovative medicines, highlighted its pipeline including givastomig, a Claudin 18.2 X 4-1BB bispecific antibody for gastric cancer, and VIS-101, a dual VEGF-A X AN...
05-28 11:00
NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Biosciences announced that its management team will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. The event will feature a fireside chat at 3:30 PM ET, with a webcast available on NovaBridge's website for 90 days. NovaBridge, a global biotech company focused on accelerating innovative medicines, highlighted its pipeline, including givastomig, a Claudin 18.2 X 4-1BB bispecific antibody for...
05-12 11:00
Alpha Buying: Insider Conviction in High-Risk Biotech
Insider buying matters in every industry, but it carries a special weight in bi...
05-08 00:04
NovaBridge Biosciences Appoints Mark Hagler As President And Chief Commercial Officer
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussionsStrong industry reputation and commercial track record in
04-22 19:11
I-Mab Biopharma GAAP EPS of -$0.48
I-Mab Biopharma press release (NBP): FY GAAP EPS of -$0.48. As of December 31, 2025, the Company had cash, cash equivalents, and short-term investments of $210.8 million. The Company’s current cash po...
04-08 05:26
NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement
NovaBridge Biosciences director Conor Chia-hung Yang files initial beneficial ownership statement NovaBridge Biosciences director Conor Chia-hung Yang reported employee share options covering 148,623 ADSs, per an initial beneficial ownership filing dated March 18, 2026. Disclaimer: This news brief w
04-01 18:12
